Effects of salvianolic acid B on protein expression in human umbilical vein endothelial cells

Huey Chun Huang, Tsong Min Chang, Guey Yueh Shi, Hua Lin Wu, Chieh Hsi Wu, Yan Di Su, Hui Lin Wang, Hsin Yun Wen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Salvianolic acid B (Sal B), a pure water-soluble compound extracted from Radix Salviae miltiorrhizae, has been reported to possess potential cardioprotective efficacy. To identify proteins or pathways by which Sal B might exert its protective activities on the cardiovascular system, two-dimensional gel electrophoresis-based comparative proteomics was performed, and proteins altered in their expression level after Sal B treatment were identified by MALDI-TOF MS/MS. Human umbilical vein endothelial cells (HUVECs) were incubated at Sal B concentrations that can be reached in human plasma by pharmacological intervention. Results indicated that caldesmon, an actin-stabilizing protein, was downregulated in Sal B-exposed HUVECs. Proteins that showed increased expression levels upon Sal B treatment were vimentin, T-complex protein 1, protein disulfide isomerase, tropomyosin alpha, heat shock protein beta-1, UBX domain-containing protein 1, alpha enolase, and peroxiredoxin-2. Additionally, Sal B leads to increased phosphorylation of nucleophosmin in a dose-dependent manner and promotes proliferation of HUVECs. We found that Sal B exhibited a coordinated regulation of enzymes and proteins involved in cytoskeletal reorganization, oxidative stress, and cell growth. Our investigation would provide understanding to the endothelium protection information of Sal B.

Original languageEnglish
Article number213050
JournalEvidence-based Complementary and Alternative Medicine
Volume2011
DOIs
Publication statusPublished - 2011
Externally publishedYes

Fingerprint

Human Umbilical Vein Endothelial Cells
Proteins
Phosphopyruvate Hydratase
HSP27 Heat-Shock Proteins
Calmodulin-Binding Proteins
Protein Disulfide-Isomerases
Peroxiredoxins
Computer Security
Tropomyosin
salvianolic acid B
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Electrophoresis, Gel, Two-Dimensional
Vimentin
Cardiovascular System
Proteomics
Endothelium
Actins
Oxidative Stress
Down-Regulation
Phosphorylation

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

Effects of salvianolic acid B on protein expression in human umbilical vein endothelial cells. / Huang, Huey Chun; Chang, Tsong Min; Shi, Guey Yueh; Wu, Hua Lin; Wu, Chieh Hsi; Su, Yan Di; Wang, Hui Lin; Wen, Hsin Yun.

In: Evidence-based Complementary and Alternative Medicine, Vol. 2011, 213050, 2011.

Research output: Contribution to journalArticle

Huang, Huey Chun ; Chang, Tsong Min ; Shi, Guey Yueh ; Wu, Hua Lin ; Wu, Chieh Hsi ; Su, Yan Di ; Wang, Hui Lin ; Wen, Hsin Yun. / Effects of salvianolic acid B on protein expression in human umbilical vein endothelial cells. In: Evidence-based Complementary and Alternative Medicine. 2011 ; Vol. 2011.
@article{0b16a2ca124e44a3a559bdda50040a6b,
title = "Effects of salvianolic acid B on protein expression in human umbilical vein endothelial cells",
abstract = "Salvianolic acid B (Sal B), a pure water-soluble compound extracted from Radix Salviae miltiorrhizae, has been reported to possess potential cardioprotective efficacy. To identify proteins or pathways by which Sal B might exert its protective activities on the cardiovascular system, two-dimensional gel electrophoresis-based comparative proteomics was performed, and proteins altered in their expression level after Sal B treatment were identified by MALDI-TOF MS/MS. Human umbilical vein endothelial cells (HUVECs) were incubated at Sal B concentrations that can be reached in human plasma by pharmacological intervention. Results indicated that caldesmon, an actin-stabilizing protein, was downregulated in Sal B-exposed HUVECs. Proteins that showed increased expression levels upon Sal B treatment were vimentin, T-complex protein 1, protein disulfide isomerase, tropomyosin alpha, heat shock protein beta-1, UBX domain-containing protein 1, alpha enolase, and peroxiredoxin-2. Additionally, Sal B leads to increased phosphorylation of nucleophosmin in a dose-dependent manner and promotes proliferation of HUVECs. We found that Sal B exhibited a coordinated regulation of enzymes and proteins involved in cytoskeletal reorganization, oxidative stress, and cell growth. Our investigation would provide understanding to the endothelium protection information of Sal B.",
author = "Huang, {Huey Chun} and Chang, {Tsong Min} and Shi, {Guey Yueh} and Wu, {Hua Lin} and Wu, {Chieh Hsi} and Su, {Yan Di} and Wang, {Hui Lin} and Wen, {Hsin Yun}",
year = "2011",
doi = "10.1155/2011/213050",
language = "English",
volume = "2011",
journal = "Evidence-based Complementary and Alternative Medicine",
issn = "1741-427X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Effects of salvianolic acid B on protein expression in human umbilical vein endothelial cells

AU - Huang, Huey Chun

AU - Chang, Tsong Min

AU - Shi, Guey Yueh

AU - Wu, Hua Lin

AU - Wu, Chieh Hsi

AU - Su, Yan Di

AU - Wang, Hui Lin

AU - Wen, Hsin Yun

PY - 2011

Y1 - 2011

N2 - Salvianolic acid B (Sal B), a pure water-soluble compound extracted from Radix Salviae miltiorrhizae, has been reported to possess potential cardioprotective efficacy. To identify proteins or pathways by which Sal B might exert its protective activities on the cardiovascular system, two-dimensional gel electrophoresis-based comparative proteomics was performed, and proteins altered in their expression level after Sal B treatment were identified by MALDI-TOF MS/MS. Human umbilical vein endothelial cells (HUVECs) were incubated at Sal B concentrations that can be reached in human plasma by pharmacological intervention. Results indicated that caldesmon, an actin-stabilizing protein, was downregulated in Sal B-exposed HUVECs. Proteins that showed increased expression levels upon Sal B treatment were vimentin, T-complex protein 1, protein disulfide isomerase, tropomyosin alpha, heat shock protein beta-1, UBX domain-containing protein 1, alpha enolase, and peroxiredoxin-2. Additionally, Sal B leads to increased phosphorylation of nucleophosmin in a dose-dependent manner and promotes proliferation of HUVECs. We found that Sal B exhibited a coordinated regulation of enzymes and proteins involved in cytoskeletal reorganization, oxidative stress, and cell growth. Our investigation would provide understanding to the endothelium protection information of Sal B.

AB - Salvianolic acid B (Sal B), a pure water-soluble compound extracted from Radix Salviae miltiorrhizae, has been reported to possess potential cardioprotective efficacy. To identify proteins or pathways by which Sal B might exert its protective activities on the cardiovascular system, two-dimensional gel electrophoresis-based comparative proteomics was performed, and proteins altered in their expression level after Sal B treatment were identified by MALDI-TOF MS/MS. Human umbilical vein endothelial cells (HUVECs) were incubated at Sal B concentrations that can be reached in human plasma by pharmacological intervention. Results indicated that caldesmon, an actin-stabilizing protein, was downregulated in Sal B-exposed HUVECs. Proteins that showed increased expression levels upon Sal B treatment were vimentin, T-complex protein 1, protein disulfide isomerase, tropomyosin alpha, heat shock protein beta-1, UBX domain-containing protein 1, alpha enolase, and peroxiredoxin-2. Additionally, Sal B leads to increased phosphorylation of nucleophosmin in a dose-dependent manner and promotes proliferation of HUVECs. We found that Sal B exhibited a coordinated regulation of enzymes and proteins involved in cytoskeletal reorganization, oxidative stress, and cell growth. Our investigation would provide understanding to the endothelium protection information of Sal B.

UR - http://www.scopus.com/inward/record.url?scp=79955098623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955098623&partnerID=8YFLogxK

U2 - 10.1155/2011/213050

DO - 10.1155/2011/213050

M3 - Article

VL - 2011

JO - Evidence-based Complementary and Alternative Medicine

JF - Evidence-based Complementary and Alternative Medicine

SN - 1741-427X

M1 - 213050

ER -